DJ-1 as a Marker for Cisplatin Resistance in Lung Cancer
Author Information
Author(s): Zeng Hua-Zong, Qu Yi-Qing, Zhang Wen-Jun, Xiu Bing, Deng An-Mei, Liang Ai-Bin
Primary Institution: Tongji University
Hypothesis
The study aims to identify cisplatin-resistance associated biomarkers for non-small cell lung cancers (NSCLC).
Conclusion
DJ-1 is associated with cisplatin resistance and may serve as a novel biomarker for predicting the response of NSCLC patients to chemotherapy.
Supporting Evidence
- High expression of DJ-1 was associated with a higher frequency of cisplatin resistance in NSCLC patients.
- Patients with high DJ-1 expression had a significantly shorter overall survival time.
- Silencing DJ-1 increased the sensitivity of lung cancer cells to cisplatin.
Takeaway
Researchers found that a protein called DJ-1 helps lung cancer cells resist a common chemotherapy drug, and measuring DJ-1 levels could help doctors predict how well patients will respond to treatment.
Methodology
The study used two-dimensional electrophoresis (2-DE) and MALDI-TOF mass spectrometry to compare protein expression in cisplatin-sensitive and -resistant lung cancer cell lines.
Limitations
The study did not perform multivariate analysis due to lack of other variables related to overall survival.
Participant Demographics
67 locally advanced NSCLC patients, including 37 squamous cell carcinomas and 30 adenocarcinomas.
Statistical Information
P-Value
0.020
Statistical Significance
p=0.020
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website